US-based MediBeacon Inc. has reached a $30 million deal giving China’s Huadong Medicine Co. Ltd. exclusive rights to its portfolio in China, Hong Kong, Macau and Taiwan, according to a statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
